I’m sure there will be plenty more resignations this month and next month. There are a good amount of opportunities nationwide with companies that have 2 things we don’t...financial stability and a pipeline. I think everyone is just one good offer away from getting off this sinking ship.
Alimera Sciences affirms record Q4 and FY2018 revenues Jan. 7, 2019 7:47 AM•Niloofer Shaikh Alimera Sciences (NASDAQ:ALIM) expectsQ4 net revenue in excess of $13M and FY2018 revenues in excess of $45M.
Big Deal! Alimera will still post a loss in the millions for the quarter and still have not made a single dollar in profit. We have been in the negative since the start. The stock will continue to teeter above and below 1 dollar for all of 2019. If the company can even make it through the year. And if they miraculously ever become profitable don’t forget about the royalties that are paid to Eyepoint to in-license ILUVIEN. Just because they had a record quarter doesn’t mean they are close to being profitable and stable.
We sell inventory to a distributor and it’s a “record quarter”. At this point in the game it doesn’t matter what our quarterly sales are at, what matters is our stock value, which is in the toilet. Our sales have been below par since launch.
Don’t leave! Securities to be offered to employees in employee benefit plans http://www.conferencecalltranscripts.org/no/summary2/?id=5671017
BUSINESS BANKRUPTCY In today’s economic climate, bankruptcy is increasingly used as an effective tool to achieve business goals. Chapter 11 can provide a business with numerous financial options to help it survive and ultimately thrive in the future. When it becomes necessary to wind down the company and liquidate assets, Chapter 7 may sometimes be the best available alternative.
Now former Alimerian german director , ruins next ITF Pharma , OMG this jerk can´t count sales or numbers